Lancet
Lancet
Audio Summaries
Lancet (London, England)
Every issue of Lancet moves the field forward, but reading every paper cover-to-cover isn't realistic. OSLR turns each article into a 3-minute audio summary so you can stay current while you commute, round, or work out.
Specialties
Lancet covers research in these specialties.
Recent summaries
The latest articles summarized from Lancet.
Spontaneous coronary artery dissection: implications for women's health, clinical care, and future research.
Nov 19, 2026
Spontaneous coronary artery dissection (SCAD) is an increasingly recognized cause of acute coronary syndromes, mainly affecting younger women, and is likely more common than previously thought. This Review synthesizes current evidence on SCAD's epidemiology, mechanisms (including genetic susceptibility), diagnosis, management, and implications for reproductive and women's health. It also identifies research priorities, since evidence guiding pharmacological and interventional treatment remains scarce, even though most patients heal spontaneously and are best managed conservatively.
Seasonal mass vaccination with R21/Matrix-M against malaria in The Gambia and Burkina Faso: an open-label, cluster-randomised, controlled trial.
Nov 19, 2026
This cluster-randomised trial asked whether seasonal mass vaccination with the R21/Matrix-M malaria vaccine, given before peak transmission, could reduce malaria infection prevalence and be safe in The Gambia (low-to-moderate transmission) and Burkina Faso (intense seasonal transmission). Across 54 villages, three monthly doses reduced the odds of P. falciparum infection at peak transmission by 70% in The Gambia (aOR 0.30) and by 25% in Burkina Faso (aOR 0.75), with the vaccine judged safe and well tolerated. The authors conclude that seasonal mass vaccination could be an additional malaria control strategy in seasonal transmission settings, though its effect was considerably larger in The Gambia than in Burkina Faso.
Reproductive health in women in Britain from 2010 to 2024: findings from repeated, cross-sectional National Surveys of Sexual Attitudes and Lifestyles (Natsal).
Nov 19, 2026
This study compares reproductive health indicators among women aged 16-54 in Britain using nationally representative Natsal surveys from 2010-2012 (Natsal-3) and 2022-2024 (Natsal-4), asking whether reproductive autonomy has improved and how it varies across social groups. Key findings include an increase in lifetime abortion (16.0% to 20.7%), a rise in women aged 16-44 reporting they definitely do not want children (7.7% to 16.6%), and a sharp drop in hormonal contraception use among women under 35. Persistent gaps remain: 18.5% of women at risk of unintended pregnancy reported no effective contraception, and women with lower education, greater deprivation, or Black African/Caribbean/Black British ethnicity faced higher risks of no effective contraception and abortion.
Natural ligand-based CAR T-cell therapy targeting BCMA and TACI for relapsed or refractory multiple myeloma (TriPRIL): a non-randomised, phase 1, first-in-human trial.
Nov 17, 2026
This first-in-human phase 1 trial tested TriPRIL, an autologous CAR T-cell therapy that uses an engineered trimeric form of the natural ligand APRIL to simultaneously target BCMA and TACI, aiming to reduce antigen escape in relapsed or refractory multiple myeloma. In 15 infused patients (nine of whom had prior BCMA-directed CAR T therapy), the therapy showed a manageable safety profile, with no dose-limiting toxicities or treatment-related deaths, and cytokine release syndrome was limited to grade 1-2. The recommended phase 2 dose was set at 3.0 × 10^8 cells, supporting further investigation of this dual-targeted, natural ligand-based approach.
Lynch syndrome.
Nov 12, 2026
Lynch syndrome, caused by germline mismatch repair gene variants, is the most common inherited cancer predisposition syndrome, yet most carriers remain undiagnosed. This review asks how scientific advances in biology, diagnosis, prevention, and treatment can be translated into equitable, effective care across the full continuum, from case identification through cascade testing. The authors highlight that universal tumour testing and immune checkpoint inhibitors have transformed the field, but that inconsistent implementation and access gaps continue to limit benefit.
Empirical tuberculosis treatment in infants living with HIV hospitalised with severe pneumonia in Africa (EMPIRICAL): a multicentre, randomised, open-label, 2 × 2 factorial, controlled superiority trial.
Nov 12, 2026
The EMPIRICAL trial asked whether starting empirical tuberculosis treatment for HIV-exposed infants hospitalised with severe pneumonia in Africa reduces mortality compared with a microbiologically and clinically guided approach. In this factorial randomised trial of 558 infants, empirical TB treatment did not significantly reduce all-cause mortality at 12 months (48% vs 43% died; adjusted HR 1.12, 95% CI 0.87-1.43), though nearly half of the comparison group eventually started TB treatment, which may have diluted the contrast. The findings indicate no evidence that empirical TB treatment is superior to the current guided strategy, while valganciclovir showed no interaction with it.
Trevogrumab (anti-GDF8) with or without garetosmab (anti-activin A) for prevention of muscle loss during semaglutide-induced weight reduction in people with obesity (COURAGE): a two-part, phase 2, double-blind, placebo-controlled, randomised trial.
Nov 11, 2026
The COURAGE trial asked whether blocking myostatin (GDF8) with trevogrumab, alone or combined with activin A blockade via garetosmab, could preserve lean mass during semaglutide-induced weight loss in adults with obesity. Trevogrumab significantly preserved lean mass relative to semaglutide plus placebo (about +1.5% to +3.1% treatment differences, depending on dose and part), and trevogrumab was generally well tolerated, whereas the trevogrumab 400 mg plus garetosmab combination produced more fat loss and weight loss but had a high rate of serious adverse events, treatment discontinuations, and two deaths (not causally linked to treatment), with more frequent muscle spasms.
A blended digital parenting intervention for the prevention of sexual violence, exploitative sex, and maltreatment of children at scale in Tanzania: a cluster-randomised, controlled trial.
Nov 10, 2026
This cluster-randomised trial in Tanzania tested whether ParentApp, a low-cost blended digital parenting programme that adds sexual violence prevention to the WHO-UNICEF Parenting for Lifelong Health curriculum, could reduce sexual violence and maltreatment against adolescents aged 10-17 compared with a water, sanitation, and hygiene (WASH) control app. Across 80 sub-wards, ParentApp significantly reduced past-month sexual violence victimisation for adolescent girls (IRR 0.43) but not boys, and it lowered maltreatment and high-risk exposure for both girls and boys according to adolescent and caregiver reports. The authors conclude that this affordable approach (about US$6 per family at scale) could help prevent childhood sexual violence and maltreatment in low-resource settings, with no adverse events reported.
Reframing disease elimination: an update from the Lancet Commission on chronic obstructive pulmonary disease.
Nov 10, 2026
This Lancet Commission update asks whether COPD can be eliminated or substantially reduced as a global health burden by shifting from late-stage management to proactive, life-course prevention. The authors propose a unified framework integrating lung development and ageing biology, precision medicine, patient-centred outcomes (such as daily functioning and quality of life), and regulatory reform. They argue that COPD is a biologically heterogeneous, preventable and modifiable condition, so success should be measured by broader lifelong lung health rather than lung function and survival alone.
Cardiovascular outcomes with survodutide in adults with obesity at increased cardiovascular risk (SYNCHRONIZE-CVOT): a double-blind, randomised, placebo-controlled, phase 3 trial.
Nov 9, 2026
SYNCHRONIZE-CVOT asked whether the dual glucagon/GLP-1 receptor agonist survodutide is cardiovascularly safe in adults with obesity and either established cardiovascular disease, chronic kidney disease, or elevated cardiovascular risk. In this randomised, placebo-controlled trial of 5,530 participants followed for a median of 22 months, the primary composite endpoint occurred in 3.7% of survodutide-treated participants versus 4.1% on placebo (HR 0.89, 95% CI 0.67–1.18), meeting the prespecified non-inferiority criterion. Gastrointestinal adverse events, particularly nausea and vomiting, were substantially more common with survodutide, though serious adverse event rates were similar across groups.
